EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the compa-ny needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to the public markets, leading the company through a unique – and small IPO. With $4 million from the offering, the company signed an agreement with Valeant Pharmaceuticals Inc. to help fund the trial. The partnership enabled the company to raise another $10 million from investors, putting it on track to start a confirmatory Phase III clinical trial.